Table 3 Chest CT evaluations of Covid-19 complicated with pulmonary fibrosis patients.
From: Proteomics and metabonomics analyses of Covid-19 complications in patients with pulmonary fibrosis
Finding | All pulmonary fibrosis patients (n = 40) | Nonprogressive pulmonary fibrosis (n = 10) | Progressive pulmonary fibrosis (n = 30) | |||
|---|---|---|---|---|---|---|
Onset | Endpoint | Onset | Endpoint | Onset | Endpoint | |
NO. of fibrotic lobes | ||||||
0 | 6 (15.0) | 0 (0) | 0 (0) | 0 (0) | 6 (20.0) | 0 (0) |
1 | 3 (7.5) | 2 (5.0) | 2 (20.0) | 2 (20.0) | 1 (3.3) | 0 (0) |
2 | 1 (2.5) | 1 (2.5) | 0 (0) | 0 (0) | 1 (3.3) | 1 (3.3) |
3 | 6 (15.0) | 4 (10.0) | 2 (20.0) | 2 (20.0) | 4 (13.3) | 2 (6.7) |
4 | 5 (12.5) | 7 (17.5) | 1 (10.0) | 3 (30.0) | 4 (13.3) | 4 (13.3) |
5 | 19 (47.5) | 26 (65.0) | 5 (50.0) | 3 (30.0) | 14 (46.7) | 23 (76.7) |
Frequency of fibrotic lobe involvement | ||||||
Right upper lobe | 22 (55.0) | 31 (77.5) | 6 (60.0) | 5 (50.0) | 16 (53.3) | 26 (86.7) |
Right middle lobe | 28 (70.0) | 34 (85.0) | 7 (70.0) | 7 (70.0) | 21 (70.0) | 27 (90.0) |
Right lower lobe | 32 (80.0) | 36 (90.0) | 9 (90.0) | 7 (70.0) | 23 (76.7) | 29 (96.7) |
Left upper lobe | 27 (67.5) | 34 (85.0) | 6 (60.0) | 7 (70.0) | 21 (70.0) | 27 (90.0) |
Left lower lobe | 31 (77.5) | 39 (97.5) | 9 (90.0) | 9 (90.0) | 22 (73.3) | 30 (100.0) |
*Total pulmonary fibrosis severity score, median (interquartile) | 5.0 (2.3–7.0) | 7.0 (5.0–11.5) | 5.0 (3.5–5.3) | 4.5 (3.5–5.3) | 6.0 (1.8–7) | 8.0 (5.0–14.0) |
